What Researchers Did
This review article explored the theoretical benefits and practical challenges of using perfluorocarbons (PFCs) as a non-recompressive treatment for decompression illness (DCI).
What They Found
Numerous animal studies since the 1980s have shown that intravenous emulsion-based perfluorocarbons significantly improve survival and reduce decompression illness symptoms. However, issues like limited shelf-life, extended organ retention, and severe side effects, primarily due to emulsifiers, have prevented human approval. Encapsulating perfluorocarbons with amphiphilic biopolymers like albumin is a new approach to achieve biocompatibility without toxic emulsifiers.
What This Means for Canadian Patients
If approved, perfluorocarbons could offer a more accessible treatment option for decompression illness, especially in remote areas where hyperbaric chambers are unavailable. This could potentially improve outcomes for patients experiencing DCI by providing a non-recompressive therapy.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The primary limitation highlighted is the current inability to translate the theoretical benefits of perfluorocarbons into approved human treatment due to formulation challenges and safety concerns.